Celladon has previously raised $61m in its first three rounds of funding, Xconomy said.
Celladon, a US-based healthcare company developing gene therapy treatments for heart attacks, has raised $250,000 in debt and securities, according to a recent regulatory filing first seen by news provider Xconomy.
Celladon said its investors included Johnson & Johnson Development Corporation, the corporate venturing unit of the eponymous US-based healthcare company, and venture capital firms Enterprise Partners Venture Capital and Venrock.
Celladon has previously raised $61m in its first three rounds of funding, Xconomy said.
